Formula invention, (I) Wherein, having 1 or 2 nitrogen atoms as ring members, optionally, independently of one another, Q is halogen, CN, NO 2, CO 2 R 4, COR 5, C 1 -C 4 - - C 1 -C 4 alkyl and be a hetero aromatic group bearing the substituents R a 1 or 2 is selected from haloalkyl, 6-membered divalent or phenyl, Ar is, or 1 as ring members has two nitrogen atoms, optionally, halogen, NO 2, CN, CO 2R 4, COR 5, C 1 -C 6 - alkyl, C 2 -C 6 - alkenyl, C 2 -C 6 - alkynyl , C 3 -C 6 - to carry a substituent R b in one or two haloalkyl - cycloalkyl, C 3 -C 6 - C 1 -C 4 alkyl and - cycloalkyl -C 1 -C 4 , The R b two groups attached to adjacent carbon atoms of Ar is C 3 -C 4 together - it is possible the alkylene is an heteroaromatic group to the 6-membered R 1 is hydrogen, C 1 -C 4 - alkyl, C 1 -C 4 - haloalkyl, C 3 -C 6 - cycloalkyl, C 3 -C 6 - cycloalkyl -C 1 -C 4 - alkyl, C 1 -C 4 - hydroxyalkyl , C 1 -C 4 - alkoxy--C 1 -C 4 - alkyl, C 3 -C 4 - C 3 -C 4 alkenyl or - there alkynyl n, R and 3, R 4 R 1, R 2, R N a] have the meanings given in the claims 5 - [(piperazinyl) hetaryl] arylsulfonamide compounds, and acid addition salts are physiologically acceptable compounds and their N- oxides of these, dopamine D for treating a disease which responds to the action by agonists, for the treatment of renal diseases and disorders of the central nervous system in particular, with auxiliary substances and a physiologically acceptable carrier and timely / or claim 3 receptor antagonists to any of items 1 described at least one N - and [(piperazinyl) hetaryl] arylsulfonamide compounds or / and at least an acid addition salt is physiologically acceptable I at least one of the I single 1 N- to pharmaceutical compositions containing oxide.本発明は、一般式(I)[式中、Qは、環成員として1又は2個の窒素原子を有し、場合により、互いに独立して、ハロゲン、CN、NO2、CO2R4、COR5、C1-C4-アルキル及びC1-C4-ハロアルキルから選択される1又は2個の置換基Raを担持する、二価の6員へテロ芳香族基であり;Arは、フェニル又は、環成員として1又は2個の窒素原子を有し、場合により、ハロゲン、NO2、CN、CO2R4、COR5、C1-C6-アルキル、C2-C6-アルケニル、C2-C6-アルキニル、C3-C6-シクロアルキル、C3-C6
